Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.1 (alkaline phosphatase)
 47,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An analysis of prognostic factors in small cell lung cancer has been carried out using data from 371 patients treated with identical chemotherapy in the context of a large prospectively randomized clinical trial. Prognosis was shown to be strongly correlated with initial performance status, disease extent, and routine biochemical tests at the time of diagnosis. Plasma albumin, plasma sodium, alkaline phosphatase, and gamma-glutamyl transpeptidase were all predictive of survival. An initial hemoglobin of less than 11 g/dl was also predictive, but age, sex, and initial WBC count were not. A multiple regression analysis identified performance status, plasma alkaline phosphatase, plasma sodium, disease extent, and plasma albumin as contributing independently to survival. Using these parameters, three prognostic groupings could be defined. The combination of performance status and the biochemical values more closely predicted survival than categorization on the basis of disease extent defined by clinical, radiological, and scanning criteria. Response to chemotherapy was strongly correlated with these prognostic groupings. A much higher response rate occurred in patients in the best prognostic category in whom the tumor mass is assumed to be smaller. These results provide a simple basis for predicting prognosis in small cell lung cancer and indicate that the better prognosis in chemotherapy responders is not solely due to the treatment.
 ...
PMID:Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. 298 56

From a total of 874 patients with small cell lung cancer (SCC), a series of 104 patients were reviewed to determine if bone marrow relapses are detectable by routine clinical investigations. Autopsy, including microscopical bone marrow examination, was performed in all the 104 patients and bone metastases were disclosed in 36 patients (35%). After retrospective evaluation it was concluded that dose modification, occurrence of leukopenia plus fever, need of blood transfusion, leukopenia, and thrombopenia during treatment all were without predictive value in the detection of bone marrow relapse. Increased concentrations of lactate dehydrogenase and alkaline phosphatase were, however, positively correlated to the finding of bone marrow relapse.
 ...
PMID:Detection of bone marrow relapse in patients with small cell carcinoma of the lung. 302 20

A patient is reported with small cell lung cancer treated with combination chemotherapy (cyclophosphamide, vincristine and etoposide [VP-16-213] who developed transient liver function abnormalities secondary to vincristine therapy. Serum transaminase (SGOT and SGPT) levels rose by 2 to 6 times, lactic dehydrogenase (LDH) 1.5 to 2 times, and alkaline phosphatase and gamma-glutamyl transpeptidase (GGTP) 1.5 to 2 times normal. Enzyme abnormalities were observed by the 6th day following drug administration and returned to normal between 16 and 48 days, except for the GGTP elevations which persisted longer. Vincristine has been suspected to cause liver damage and to enhance radiation-induced hepatic injury. The authors report this case of moderate transient transaminitis confirmed by rechallenge with vincristine.
 ...
PMID:Hepatotoxicity following vincristine therapy. 609 4

Radionuclide bone scans were performed before and during combination chemotherapy in 119 systematically staged patients with small cell carcinoma of the lung. Before therapy, 49 patients (41%) had positive scans. Scan positivity was significantly associated with the presence of metastatic tumor in the bone marrow, positive skeletal radiographs, and elevated serum alkaline phosphatase levels. Nonosseous distant metastases were significantly more likely to be detected as the number of areas of focal abnormalities on bone scan increased. The survival of patients with documented distant metastases in bone and nonosseous sites was significantly inferior to the survival of patients with limited disease, isolated osseous extensive disease, and extensive disease occurring only in nonbony sites. Of 36 patients with initially abnormal scans and tumor regression documented by other methods, scan findings improved in 24 (67%). In 26 (36%) of 72 scans in patients demonstrating disease progression in extraosseous sites, new areas of increased radionuclide uptake appeared. Improvement or worsening in follow-up scans was associated with nonbony tumor response or progression, respectively, 70% of the time. Serial bone scans provide reasonably accurate staging and prognostic information in patients with small cell lung cancer, although they are probably not sufficiently reliable to be used as the sole parameter in therapeutic decision-making.
 ...
PMID:Small cell lung cancer: radionuclide bone scans for assessment of tumor extent and response. 626 74

Didemnin B (NSC 325319), a cyclic depsipeptide isolated from a Carribean sea tunicate, exhibited potent antitumor activity in preclinical studies. After determining the maximum tolerated dose in our previous phase I/II trial, we conducted a phase II study of this drug in patients with previously treated small cell lung cancer; the starting dose was 6.3 mg/m2 intravenously over 30 min every 28 days. The major side effects were in the neuromuscular system and included severe muscle weakness, myopathy and/or myotonia by electromyography, and elevation of creatine phosphokinase and aldolase levels. We also observed modest increases in bilirubin and alkaline phosphatase levels. There were minimal hematologic toxic effects. No response was observed among 15 evaluable patients, leading us to conclude that didemnin B was toxic but inactive in patients with previously treated small cell lung cancer at the stated dose and schedule. A review of the literature revealed no significant antitumor activity in cancers of the colon, breast, ovaries, cervix, or lung (non-small cell) or in renal cell carcinoma. Further clinical trials for didemnin B may not be warranted at the stated dose and schedule.
 ...
PMID:Phase II clinical trial of didemnin B in previously treated small cell lung cancer. 789 44

137 patients with small cell lung cancer (SCLC) were retrospectively analysed. The median survival for all patients were 284 days, for limited disease patients 399 days, and for extensive disease patients 252 days. Univariate statistical analysis based on Kaplan-Meier-estimates and Log-Rank-Test showed the following prognostically beneficial factors: Limited disease stage (p = 0.009), NSE serum level less than 25 micrograms/l (p = 0.016), serum alkaline phosphatase less than 200 U/l (p = 0.035), normal serum albumin (p = 0.003) and activity index of minimum of 70 (p < 0.001). The patient age and sex did not image as relevant prognostical factors.
 ...
PMID:[Prognostic factors of small-cell bronchial carcinoma]. 793 56

We retrospectively reviewed the charts of 151 consecutive patients diagnosed as small cell lung cancer in our department and who had at least one course of chemotherapy. Nineteen patients died during the first 2 months, of the probability were reported to construct a receiver operating characteristic curve i.e. 13% of the population. The probability of dying within 2 months was investigated through a stepwise logistic regression. A performance status < or = 70 (Karnofsky index), an age > 60, a platelet count < or = 150,000/mm3, elevated alkaline phosphatase and a sodium < or = 135 mmol/l were independent predictors of a very short term survival and contributed to the equation for the probability of dying within a 2-month period. Sensitivity and specificity for various cutoff points characteristic curve allowing one to determine for a given patient his risk of being a very short term survivor. Such an approach could prevent inclusion of patients with high risk of early death in clinical trials and help to choose appropriate treatments for such poor risk patients.
 ...
PMID:Can we predict very short term survival in small cell lung cancer? 807 68

Disease extent, performance status (PS), and serum lactate dehydrogenase (LDH) are the most important prognostic factors in both inoperable non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Hyponatremia and serum alkaline phosphatase play an additional role in SCLC. Many different stratification algorithms have been proposed in SCLC but a general consensus cannot be achieved before it is decided whether stage of disease should rank above or be included in an algorithm, along with other prognostic factors.
 ...
PMID:Factors confounding evaluation of treatment effect in lung cancer. 808 32

Bone marrow bilateral biopsy was done in 106 small cell lung cancer patients before treatment. Full blood count, serum alkaline phosphatase activity, serum albumin concentration and serum Na+ concentration were compared according to presence or absence of bone marrow metastases. Decreased red cell count and elevated alkaline phosphatase activity were found significantly more often in the group of patients with bone marrow involvement. Thrombocytopenia and "blast" smear occurred only in patients with bone marrow metastases. Although bone marrow was found more often in association with low albumin level, this was not significant. It was impossible to anticipate the presence of bone marrow metastases on the base of total blood count, examination increased serum alkaline phosphatase activity or decreased serum Na+ or albumin levels. However in the presence of thrombocytopenia and "blastic" smear bone marrow metastases are very probable.
 ...
PMID:[Frequency of bone marrow involvement in patients with small cell lung carcinoma before treatment based on selected laboratory parameters]. 811 24

Sulofenur is a member of a new class of antineoplastic agents with a novel chemical structure and unique pharmacological and biological properties. Preclinical studies have demonstrated a wide spectrum of anti-tumor activity against murine solid tumors and human tumor xenografts. In phase I trials, only mild toxicities were observed. Twenty-six patients (pts), two of whom were inevaluable, with advanced non small cell lung cancer without prior chemotherapy were entered on this phase II trial. Pts received 800 mg/m2 sulofenur po Monday-Friday x 21 days, q 28 days. Seventeen male and 9 female pts with median performance status 1 received a median of 2 courses. Twenty pts had stage IV disease and 19 pts had adenocarcinoma, 6 squamous cell and 1 undifferentiated carcinoma. The main toxicity was grade 1 to 3 anemia in 16 (62%) pts, with hemolysis noted in 9 pts. Although methemoglobinemia was observed in 19 pts, it was severe in only 3 pts. Transient elevation of alkaline phosphatase was seen in 11 pts and one pt had a minor abnormality in glucose metabolism. Other common chemotherapy related side effects such as granulocytopenia or alopecia were not encountered with this agent. Of 24 evaluable pts, two pts had stable disease or minor response and 22 pts had progressive disease. In conclusion although sulofenur had only minor side effects, in the dosage and schedule used, it did not produce any significant response in advanced non-small cell lung cancer.
 ...
PMID:Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer. 839 98


<< Previous 1 2 3 4 Next >>